These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 17103075)
1. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study. D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075 [TBL] [Abstract][Full Text] [Related]
2. Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Aussilhou B; Dokmak S; Faivre S; Paradis V; Vilgrain V; Belghiti J Ann Surg Oncol; 2009 Jun; 16(6):1553-9. PubMed ID: 19363584 [TBL] [Abstract][Full Text] [Related]
3. Volumetric analysis of remnant liver regeneration after major hepatectomy in bevacizumab-treated patients: a case-matched study in 82 patients. Millet G; Truant S; Leteurtre E; Hebbar M; Zerbib P; Huet G; Boleslawski E; Pruvot FR Ann Surg; 2012 Nov; 256(5):755-61; discussion 761-2. PubMed ID: 23095619 [TBL] [Abstract][Full Text] [Related]
4. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study. Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613 [TBL] [Abstract][Full Text] [Related]
5. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565 [TBL] [Abstract][Full Text] [Related]
6. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. Scappaticci FA; Fehrenbacher L; Cartwright T; Hainsworth JD; Heim W; Berlin J; Kabbinavar F; Novotny W; Sarkar S; Hurwitz H J Surg Oncol; 2005 Sep; 91(3):173-80. PubMed ID: 16118771 [TBL] [Abstract][Full Text] [Related]
7. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer. Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S; Oncology; 2013; 84(1):14-21. PubMed ID: 23076023 [TBL] [Abstract][Full Text] [Related]
9. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study. Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168 [TBL] [Abstract][Full Text] [Related]
10. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643 [TBL] [Abstract][Full Text] [Related]
12. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases. Neeff HP; Drognitz O; Klock A; Illerhaus G; Opitz OG; Hopt UT; Makowiec F Int J Colorectal Dis; 2012 May; 27(5):635-45. PubMed ID: 22139030 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels. Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946 [TBL] [Abstract][Full Text] [Related]
14. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574 [TBL] [Abstract][Full Text] [Related]
15. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049 [TBL] [Abstract][Full Text] [Related]
16. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. Cheon EC; Small W; Strouch MJ; Krantz SB; Rademaker A; Mulcahy MF; Benson AB; Bentrem DJ; Talamonti MS J Surg Oncol; 2010 Oct; 102(5):539-42. PubMed ID: 20812264 [TBL] [Abstract][Full Text] [Related]
17. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases. Petrelli NJ J Clin Oncol; 2009 Apr; 27(11):1917; author reply 1918. PubMed ID: 19255304 [No Abstract] [Full Text] [Related]
18. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases. van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819 [TBL] [Abstract][Full Text] [Related]
19. Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. Mahfud M; Breitenstein S; El-Badry AM; Puhan M; Rickenbacher A; Samaras P; Pessaux P; Lopez-Ben S; Jaeck D; Figueras J; Alain-Clavien P World J Surg; 2010 Jan; 34(1):92-100. PubMed ID: 19838754 [TBL] [Abstract][Full Text] [Related]
20. Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based? Bilchik AJ; Hecht JR J Clin Oncol; 2008 Apr; 26(11):1786-8. PubMed ID: 18398144 [No Abstract] [Full Text] [Related] [Next] [New Search]